Salute e Benessere

Inventiva announces a €20.1 million issuance of royalty certificates

Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng).Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United Kingdom over a 14-year term.Cash runway extended through September 2024 and evaluation of strategic and financing options pursued 1.Daix (France), Long Island City (New York, United States), July 18, 2024– Inventiva (Euronext Paris and Nasdaq:...
Nasdaq GlobeNewswire
18/07/2024

NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment…

Published in NEJM, the pivotal XTEND-Kids study shows ALTUVOCT met primary and key secondary endpoints, which included occurrence of factor VIII inhibitors and annualised bleed rates (ABRs). Results revealed no development of factor VIII inhibitors and sustained protection from bleeding events with once-weekly dosing. These findings support the value of sustaining high factor levels with ALTUVOCT in children with haemophilia A. Published inNEJM, the pivotal XTEND-Kids study shows...
PR Newswire
18/07/2024

Notice of Extraordinary General Meeting in Enzymatica AB (publ)

Those who wish to participate in the annual general meeting must: Those who wish to participate in the annual general meeting must: The notice shall include full name, personal identification number or corporate registration number, address and daytime telephone number and, where appropriate, information about representative, proxy and assistants. The number of assistants may not be more than two (2). The notification should, where appropriate, be accompanied by proxies, registration...
PR Newswire
18/07/2024

Enzymatica's Board of Directors decides on a new rights issue of approximately…

Background and reasonsFor the past three years, Enzymatica's management and board have conducted structured and planned work to prepare the Company for rapid international expansion. The production capacity in the own facility in Iceland has quadrupled and major investments have been made to strengthen the regulatory and scientific documentation about the Company's patented barrier technology and the product ColdZyme. After several important advances in the first half of 2024, Enzymatica is…
PR Newswire
18/07/2024

Pharming Group to report second quarter and first half 2024 financial results on…

Leiden, the Netherlands, July 18, 2024:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024.Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on August 1, 2024. To participate in the conference call, please register in advance using the link below. Once registered,...
Nasdaq GlobeNewswire
18/07/2024

Save the date: Essity's Capital Markets Day, December 3, 2024

The day is scheduled to start around 08:00 CET and continue until around 17:00 CET. The day is scheduled to start around08:00 CETand continue until around17:00 CET. The Capital Markets Day is an opportunity for institutional investors, financial analysts and the media to receive an update on Essity's strategy and progress. More information about the event and registration will be provided shortly. The Capital Markets Day is not foreseen to be streamed live, but recorded...
PR Newswire
18/07/2024

Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business…

Financial Performance Financial Performance The Company delivered strong financial performance for the third consecutive quarter with total revenue of 54.2 MSEK. Of this, 47.1 MSEK is attributed to IDEFIRIX sales. This excludes the impact of an approximate 20 MSEK provision related to potential price adjustments from cumulative sales since the launch of IDEFIRIX inEuropein 2020. After accounting for this provision, total IDEFIRIX product sales were 27.2 MSEK. Sales performance was...
PR Newswire
18/07/2024

Nicox Provides Second Quarter 2024 Update

Press ReleaseNicox Provides Second Quarter 2024 Update Nicox Group revenue of €1.6 million (net revenue 1€1.0 million) for second quarter 2024Nicox Group cash of €7.8 million on 30 June 2024 which finances the Company until at least February 2025July 18 th, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the revenue and cash position...
Nasdaq GlobeNewswire
18/07/2024

Crossject achieves key ZEPIZURE® manufacturing milestone

Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is part of the positive manufacturing data generated since 2021Manufacturing progress supports timelines toward granting of Emergency Use Authorization (EUA)Dijon, France, July 18, 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced...
Nasdaq GlobeNewswire
18/07/2024

Essity: Interim Report, Quarter 2, 2024

CEO'S COMMENTS CEO'S COMMENTS Essity is in better shape than ever, reporting strong second-quarter earnings with good underlying growth and its highest operating profit (EBITA) to date. All business areas achieved higher EBITA margins compared with the preceding year. We presented new ambitious financial targets during the quarter, and initiated a share buyback program. Higher volumesAll categories reported higher volumes, excluding the restructuring in Professional Hygiene, and in...
PR Newswire
18/07/2024

BioSenic releases new in-depth analysis of its positive phase 2 clinical data…

Press Release The upcoming Phase 3 trial with ATO is more robust following a new post-hoc analysis.Mont-Saint-Guibert, Belgium, July 18, 2024, 7.00 am CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases therapy, today announced the final results of a new, detailed post-hoc analysis of the Company's previous Phase 2 clinical trial of ATO for the first-line curative treatment of cGvHD. The...
Nasdaq GlobeNewswire
18/07/2024

Novartis continues to deliver strong sales growth and core margin expansion in…

Ad hoc announcement pursuant to Art. 53 LR Q2 net sales grew +11% (cc 1, +9% USD) with core operating income up +19% (cc, +17% USD)Sales growth driven by continued strong performance fromEntresto(+28% cc),Kesimpta(+65% cc),Cosentyx(+22% cc),Kisqali(+50% cc),Leqvio(+134% cc) andPluvicto(+44% cc)Core operating income margin 39.6%, +270 basis points (cc), mainly driven by higher net salesQ2 operating income grew +47% (cc, +43% USD) and net income…
Nasdaq GlobeNewswire
18/07/2024

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects…

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney DiseaseNew data confirm beneficial treatment effect of varoglutamstat on kidney functionTreatment effect 1in diabetes subgroup 2of >8mL/min/1.73m2/year in estimated glomerular filtration rate (eGFR); reinforces previously reported treatment effect of 3...
Nasdaq GlobeNewswire
18/07/2024

Junshi Biosciences Announces the Acceptance of the Supplemental New Drug…

®, product code: JS001) combined with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC). Liver cancer is a common malignant tumor of the digestive system worldwide, and the predominant pathological type is HCC (accounting for about 90% of global cases). According to the 2022 GLOBOCAN Report, there were 866,000 new cases and 759,000 deaths from liver cancer globally that year. China is particularly affected by liver cancer, with new liver...
Nasdaq GlobeNewswire
18/07/2024

China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature…

Portable Medical Devices Conduce to First Aid Efficiency the World Economic Forum projects that the climate crisis could lead to an alarming increase of 14.5 million deaths by 2050. The escalating extreme weather events has raised public awareness of the importance of first aid. Chinese companies have developed more convenient medical devices to assist in on-site rescue operations. For example, a portable emergency-specific Digital Radiography (DR) system weighs only 23 kilograms, features an…
PR Newswire
18/07/2024

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its…

NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia AALTUVIIIO provides high-sustained factor levels with once-weekly dosing in children under 12 with hemophilia A XTEND-Kids results show highly effective bleed protection in hemophilia A with no inhibitor development to factor VIII Paris, July 17, 2024– Full results from the XTEND-Kids phase 3 studypublishedinTheNew England...
Nasdaq GlobeNewswire
17/07/2024

Nipro Announces Major Expansion with New Medical Device Manufacturing Facility…

Nipro to Enhance Local Production and Job CreationFounded in Japan, Nipro stands as a Tier 1 manufacturer renowned for its high-quality medical devices and healthcare solutions. Tsuyoshi Yamazaki, Senior Managing Director of Global Business at Nipro, shared his excitement about the new facility. "We are thrilled to start manufacturing our cutting-edge medical devices in the U.S., which will support local healthcare professionals and patients with a stable supply chain and reduced…
PR Newswire
17/07/2024

Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31…

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations...
PR Newswire
17/07/2024

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary…

Participants completed primary vaccination series (3 doses) with VLA15 Primary vaccination series to be followed by a booster approximately one year after completion New York, NY and Saint-Herblain (France), July 17, 2024– Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the participants of the Phase 3 trial “Vaccine Against Lyme for Outdoor Recreationists” (VALOR) have completed the primary vaccination series (three doses) of Lyme...
Nasdaq GlobeNewswire
17/07/2024

Alkermes to Report Second Quarter Financial Results on July 24, 2024

About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes also has a corporate office and research…
PR Newswire
17/07/2024

New Nature publication confirms CARBIOS' leadership in enzymatic degradation of…

CARBIOS and Toulouse Biotechnology Institute (TBI) publish groundbreaking article that presents enzyme optimization work leading to an enzyme-embedded PLA able to disintegrate and biodegrade in home-compost conditions faster than certification timeframe requirementsThis new publication inNature, widely regarded as the most influential scientific journal, comes in addition to the2020 publication on enzymatic depolymerization of PET, confirming CARBIOS' leadership in enzymatic...
Nasdaq GlobeNewswire
17/07/2024

Roche's Vabysmo showed extended durability, continued efficacy and a consistent…

More than 90% of patients had absence of DME after four years in a pre-specified exploratory endpointPeople treated with Vabysmo sustained vision gains and anatomical improvements, with almost 80% receiving treatment at intervals of three or four months, in an exploratory analysis The study met all primary endpoints, showing safety data were consistent with Vabysmo's known safety profileThis is the largest long-term extension dataset in DME to-date, demonstrating consistent...
Nasdaq GlobeNewswire
17/07/2024

Surge in Prevalence of Venous Disorders Drives Venous Stents Market to Reach US$…

The venous stents market is experiencing significant growth, driven by a combination of increasing incidence of venous obstructive disorders and a surging global geriatric population. Venous stents, crucial for treating conditions such as deep vein thrombosis (DVT) and chronic venous insufficiency, are seeing heightened demand as these conditions become more prevalent. The venous stents market is experiencing significant growth, driven by a combination of increasing incidence of venous...
PR Newswire
17/07/2024

Digital Pathology Market worth $2.0 billion by 2029 driven by Technological…

Browse in-depth TOC on "Digital Pathology Market" Browse in-depth TOC on "Digital Pathology Market" 248 - Tables47 - Figures 325 - Pages DANAHER CORPORATION (US): Leader in Digital Pathology Solutions Danaher Corporation, through its subsidiary Leica Biosystems, has established itself as a strong player in the digital pathology market, offering a comprehensive portfolio from biopsy to diagnosis across radiology, pathology, surgery, and oncology. Strategic partnerships...
PR Newswire
17/07/2024
Altri  Comunicati